Program
patritumab deruxtecan
Also written as “HER3-DXd”, “Patritumab deruxtecan” and “Patritumab Deruxtecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Esophageal Neoplasms · Neoplasms · Gastrointestinal Neoplasms, led by 2 companies.
Drug pagePatritumab deruxtecan: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 99 open or running | phase 3since Jul 2, 2025 | Nov 14, 2019 | May 9, 2028phase 2 · NCT06445972 |
| Daiichi Sankyoits history only | 86 open or running | phase 3since Apr 15, 2022 | Nov 28, 2016 | Nov 19, 2030phase 2 · NCT06172478 |
- Named in Merck’s own pipeline as
patritumab deruxtecan (MK-1022)
, phase 3, as of Nov 2, 2026 (source).
Also a collaborator on its studies: AstraZeneca.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentMerck develops it with Daiichi Sankyo, worldwide except Japan, where Daiichi Sankyo keeps the rights.Announced Oct 19, 2023 · Source: Merck, Oct 19, 2023
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2019Named patritumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 121
- Nov 14, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04165070 · 450 planned · United States, Canada, Hungary and more
- Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
- May 31, 2024Phase 2 study in Esophageal NeoplasmsNCT06445972 · 210 planned · United States, Brazil, Chile and more
- Jun 17, 2024Phase 2 study in Esophageal NeoplasmsNCT06469944 · 160 planned · United States, Brazil, Chile and more
- Sep 11, 2024Phase 2 study in Gastrointestinal NeoplasmsNCT06596694 · 180 enrolled · United States, Australia, Canada and more
- Nov 11, 2024Phase 2 study in Breast NeoplasmsNCT06686394 · 181 planned · United States, Canada, Israel and more
- Dec 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06731907 · 90 planned · United States, Chile, Greece and more
- Jan 21, 2025Phase 2 study in Breast NeoplasmsNCT06797635 · 372 planned · United States, South Korea, Spain and more
- Feb 27, 2025Phase 2 study in NeoplasmsNCT06941272 · 50 planned · United States, Australia, Belgium and more
- Jul 2, 2025Phase 3 study in Breast NeoplasmsNCT07060807 · 1,000 planned · United States, Argentina, Australia and more
- Oct 21, 2026Primary completion moved from 2030-04-18 to 2032-08-02Date moved laterphase 2 · +27 months · NCT06686394
Ahead
- May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsNCT06445972
- Dec 7, 2028Primary completion: phase 2 study in Gastrointestinal NeoplasmsNCT06596694
- Sep 12, 2029Primary completion: phase 2 study in Esophageal NeoplasmsNCT06469944
- Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsNCT06797635
TargetBeta
“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activit…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),”NCIt, by rule
“Receptor tyrosine-protein kinase erbB-3 binding agent”ChEMBL 37, by rule
Other programs on ERBB3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| beruzatatug pelitecanrule | MediLink Therapeutics (Suzhou) | phase 3 | 9 |
| ruzaltatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 8 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| SYS6023rule | CSPC Pharmaceutical Group | phase 2 | 2 |
| Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rule | xadcera-biopharmaceutical-suzhou-co-ltd | phase 2 | 1 |
| Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rule | hummingbird-bioscience | phase 2 | 1 |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
| KHN922rule | Chengdu Kanghong Pharmaceutical Group | phase 2 | 1 |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
Studies
All 9 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07060807Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jul 14, 2033 | 1,000 |
| NCT06941272Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Dec 30, 2030 | 50 |
| NCT06797635Breast Neoplasms · United States, South Korea, Spain and more | 2 | Recruiting | Dec 31, 2029 | 372 |
| NCT06731907Carcinoma, Non-Small-Cell Lung · United States, Chile, Greece and more | 2 | Recruiting | Mar 12, 2032 | 90 |
| NCT06686394Breast Neoplasms · United States, Canada, Israel and more | 2 | Recruiting | Aug 2, 2032 | 181 |
| NCT06596694Gastrointestinal Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Dec 7, 2028 | 180 |
| NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | Sep 12, 2029 | 160 |
| NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | May 9, 2028 | 210 |
| NCT04165070Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more | 2 | Recruiting | Feb 13, 2032 | 450 |
How it is read
Names in the registry
- “HER3-DXd”, 8 entries
- “Patritumab deruxtecan”, 5 entries
- “Patritumab Deruxtecan”, 5 entries
- “Patritumab Deruxtecan (Fixed dose)”, 1 entry
- “Patritumab Deruxtecan (Up-Titration)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Breast Neoplasms, 5 studies
- Esophageal Neoplasms, 2 studies
- Neoplasms, 1 study
- Gastrointestinal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.